

Annual Monitoring for Persons on Long-Term Opioid Therapy (AMO)

By working together, we can improve health outcomes for your patients, our members. Pharmacy Quality Alliance (PQA) measures are included in the Centers for Medicare and Medicaid Services (CMS) program for Marketplace members. Appropriate Medication Use measures are developed by the PQA and endorsed by the National Quality Forum. This tip sheet provides key details of the PQA measure for the annual monitoring for persons on long-term opioid therapy (AMO).

What Is the Measure?

- The measure monitors members age 18 and older who are prescribed long-term opioid therapy and have not received a drug test for any of the following: amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, and opiates/opioids at least once during the measurement year.
- A lower rate indicates better performance.

Note:

- Opioid/analgesic therapy for 90 days or more
- The prescriptions can be for the same or different opioids; including combination products.
- Compliance is determined by medical and lab claims.

Medications

The opioids below are considered for this measure.

Benzhydrocodone	Hydrocodone	Oxycodone
Buprenorphine	Hydromorphone	Oxymorphone
Butorphanol	Levorphanol	Pentazocine
Codeine	Meperidine	Tapentadol
Dihydrocodeine	Methadone	Tramadol
Fentanyl	Morphine	

Exclusions

- Medication prescribed or provided as part of medication – assisted treatment for opioid use disorders such as:
 - Buprenorphine sublingual tablets
 - Probuphine implant kit (subcutaneous implant)

Continued next page

All summaries of the measures contained herein are reproduced with permission from HEDIS Volume 1: Technical Specifications for Health Plans by the National Committee for Quality Assurance (NCQA). HEDIS® is a registered trademark of the NCQA. Please see the final page of this document for the full copyright citation.

Florida Blue is an independent licensee of the Blue Cross and Blue Shield Association.

Exclusions (continued)

- All buprenorphine/naloxone combination products
- Medications administered by IV or epidural
- Member in hospice or receiving hospice services during the measurement year
- Members receiving palliative care during the measurement year
- Members with a diagnosis of cancer

Codes for Drug Testing

Drug Test:

CPT: 80184; 80305-80307; 80324-80326; 80345-80359; 80361-80365; 80372-80373; 80375

HCPCS: G0480-G0483; G0659

Exclusion Codes

Hospice Encounter:

HCPCS: G9473-G9479; Q5003-Q5008; Q5010; S9126; T2042-T2046

Hospice Intervention:

CPT: 99377-99378

Palliative Care:

CPCS: G0182; Z51.5

References

- [CMS.gov/Files/Document/2023-QRS-Technical-Specifications.pdf](https://www.cms.gov/Files/Document/2023-QRS-Technical-Specifications.pdf)
- PQAAalliance.org/QRS

Content reproduced with permission from HEDIS® MY2024, Volume 1: Technical Specifications for Health Plans by the National Committee for Quality Assurance (NCQA). HEDIS measures and specifications are not clinical guidelines and do not establish a standard of medical care. NCQA makes no representations, warranties, or endorsement about the quality of any organization or physician that uses or reports performance measures and NCQA has no liability to anyone who relies on such measures or specifications. Limited proprietary coding sets are contained in the specifications for convenience, and users should obtain all necessary licenses from the owners of the code sets. NCQA disclaims all liability for use or accuracy of any coding contained in the specifications. To purchase copies of the publication, including the full measures and specifications, visit [NCQA.org/Publications](https://www.ncqa.org/Publications).